ADIPOQ and chronic kidney disease: Because patients with metabolic comorbidities such as obesity or chronic kidney disease, conditions known to suppress adiponectin, were excluded, other factors such as a distinct metabolic milieu or genetic/environmental influences may have contributed to the increase [28].